Daré Bioscience (NASDAQ:DARE) Given “Buy” Rating at HC Wainwright

Daré Bioscience (NASDAQ:DARE)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $12.00 price target on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 315.22% from the company’s current price.

Daré Bioscience Trading Up 0.3 %

NASDAQ:DARE opened at $2.89 on Tuesday. The company’s 50 day moving average is $3.06 and its two-hundred day moving average is $3.29. The company has a market cap of $25.14 million, a PE ratio of -4.89 and a beta of 1.38. Daré Bioscience has a twelve month low of $2.67 and a twelve month high of $7.56.

Institutional Trading of Daré Bioscience

Several large investors have recently added to or reduced their stakes in the company. AMH Equity Ltd lifted its stake in Daré Bioscience by 50.0% during the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 50,000 shares during the period. Jane Street Group LLC purchased a new position in shares of Daré Bioscience during the fourth quarter worth $52,000. Renaissance Technologies LLC lifted its position in Daré Bioscience by 6.7% during the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 4,300 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Daré Bioscience by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after purchasing an additional 3,593 shares during the last quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.